• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        In Vivo Assays for COX-2

        互联网

        1263
        The discovery of two isoforms of the cyclooxygenase (COX) enzyme, COX-1 and COX-2, has provided the rationale for development of selective COX-2 inhibitors as a class of safer drugs for the treatment of pain, symptoms of osteoarthritis and rheumatoid arthritis (see reviews 1 ,2 ). Broadly speaking, COX-1 is the constitutive “house-keeping” enzyme responsible for production of prostaglandins (PG) involved in physiological functions such as gastrointestinal cytoprotection and platelet functions. In contrast, COX-2 is rapidly and strongly upregulated upon inflammatory stimuli. COX-2 is the predominant isoform responsible for production of PGs involved in pain, inflammation, and fever. Thus, the therapeutic actions of conventional nonsteroidal antiinflammatory drugs (NSAIDs), which inhibit both COX-1 and COX-2, can be attributed to their inhibition of PG production during inflammation. On the other hand, the dose-limiting gastrointestinal toxicity of NSAIDs can be explained by their inhibitory action on COX-1. It is hypothesized that a selective COX-2 inhibitor will achieve therapeutic efficacy in osteoarthritis, rheumatoid arthritis, and pain management while substantially improved gastrointestinal toxicity profile owing to its COX-2 selectivity. This hypothesis is now supported by an extensive amount of data from preclinical and clinical studies with approved COX-2 inhibitors, such as rofecoxib (3 ) and celecoxib (4 ), and COX-2 inhibitors currently in development, such as etoricoxib (5 ) and valdecoxib (6 ).
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序